Video

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.

Transcipt (slightly modified)

What are your thoughts on providers taking on 2-sided risk?

The 2-sided risk model, I think like any challenge or any strategy, is we want to know all sides. So, what’s the upside, what’s truly the downside, where’s our floor, and how high can our ceiling go? I think we’ll know that as OCM starts to look at reconciliation and looking at numbers and data distributions. I think we’ll find that some of the oncology care models then will put their toes in the water and try to see what a risk model would look like. I think as long as these risk models are outcome based and the goal is to improve quality, I don’t think that anyone would ever want an oncology practice to not do well and go bankrupt because of a payment model that’s developed. Obviously if that happens, we’ve done something wrong and we need to fix it.

Related Videos
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Giulio Cossu, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo